Business Wire

rf IDEAS Launches End-to-End FIDO2 Credential Solution with IDmelon

6.3.2023 18:30:00 EET | Business Wire | Press release

Share

rf IDEAS, a leading manufacturer of credential readers for authentication and logical access, is pleased to announce the release of the rf IDEAS FIDO2 Passwordless Platform powered by IDmelon. This end-to-end solution brings seamless, passwordless authentication to existing credentials by converting them to FIDO2 security keys – overnight.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005278/en/

FIDO2 frees organizations from password management and risk

Nearly 90% of data breaches are due to stolen passwords or human error. Passwordless single-sign on solutions are helping to combat this challenge, and migrating to more secure credentials helps arm your team with a defense mechanism.

“Partnering with rf IDEAS, and their WAVE ID® technology was a strategic decision for IDmelon – leveraging the trust and reliability of their readers to bring the FIDO2 Passwordless Platform to market allows us to jointly deliver an end-to-end solution that organizations can deploy quickly and scale affordably,” remarked CEO and co-founder of IDmelon Bahram Piri.

The rf IDEAS FIDO2 Passwordless Platform eliminates the need for centrally stored passwords that can be hacked, as well as the risk of password theft, phishing and other user-directed cyberattacks. And for users, it’s simple to roll out and easy to use. Organizations can now enable and manage passwordless authentication across credential types, devices and platforms. This rapidly growing industry standard is supported by Microsoft, Google, Apple, and all leading web services and browsers.

Ushering in a new standard for authentication

The logical access control industry is evolving rapidly to combat cyber threats and data breaches while improving the user experience of authentication without risking governance and security.

“At rf IDEAS, we have listened to our customers and are proud to release a solution that removes the complexities of credential migration, converting users quickly and securely to a higher standard of security,” said Raul Cepeda Jr., Vice President of Product and Marketing at rf IDEAS. “Now, access via security keys is possible using existing credentials, WAVE ID readers, and the rf IDEAS Passwordless Platform – evolving the way we think about migration across credentials by leveraging ID badges and smartphones to unlock potential to more secure authentication methods.”

rf IDEAS and IDmelon will be showcasing their joint solution at the upcoming Gartner IAM symposiums in London and Texas this month – to see a full listing of upcoming events visit our Events Page.

To learn more and set up a 1:1 consultation, visit rfIDEAS.com/FIDO2.

About rf IDEAS

rf IDEAS, Inc. is a leader in logical access solutions for healthcare, manufacturing, financial, government, education and enterprise. The company’s WAVE ID readers are trusted by users across the globe and backed by strong partnerships with leading identity and access management providers. rf IDEAS readers enable innovative solutions for single sign-on, secure printing, and mobile authentication while supporting nearly all credentials worldwide. For more information, visit www.rfIDEAS.com .

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Megan Forsberg
P: 224-236-0270 x 1479
E: mforsberg@rfIDEAS.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye